Clicky

Alnylam Pharmaceuticals, Inc.(ALNY)

Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Liver Disease Cholesterol Hemophilia Liver Cancer Amyloidosis Deficiency Hypercholesterolemia Huntington's Disease Takeda Pharmaceutical Company Hemoglobin Monsanto Amyloid Antitrypsin Deficiency Hemophilia A Treatment Of Hemophilia Spinal Muscular Atrophy Alnylam Pharmaceuticals Rna Interference Transthyretin Genzyme Thalassemia Therapeutic Gene Modulation Beta Thalassemia Hemoglobinopathies Medtronic Acute Intermittent Porphyria Treatment Of Huntington's Disease

Home Page: www.alnylam.com

ALNY Technical Analysis

675 West Kendall Street
Cambridge, MA 02142
United States
Phone: 617 551 8200


Officers

Name Title
Mr. Michael W. Bonney B.A. Exec. Chairman
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB CEO & Director
Dr. Akshay K. Vaishnaw M.D., Ph.D. Pres
Mr. Jeffrey V. Poulton M.B.A. CFO & Exec. VP
Mr. Tolga Tanguler M.B.A. Exec. VP & Chief Commercial Officer
Dr. Alfred W. Boyle Ph.D. Chief Technical Operations & Quality Officer
Dr. Kevin Joseph Fitzgerald Ph.D. Sr. VP, Head of Research & Chief Scientific Officer
Ms. Christine Regan Lindenboom Sr. VP of Investor Relations & Corp. Communications
Ms. Indrani M. Lall Franchini J.D. Exec. VP, Chief Legal Officer & Sec.
Mr. Piyush Sharma J.D. Chief Ethics & Compliance Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 142.9249
Price-to-Sales TTM: 29.3666
IPO Date: 2004-05-28
Fiscal Year End: December
Full Time Employees: 1665
Back to stocks